Robert Widmer, MD
Interventional Cardiology · Temple, TXNPI 1730319252
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $98,881 of the $140,058 with a category attached, or 70.6%. 30 manufacturers reported payments, led by Abbott at 41.7% of the total. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $331.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$58K
- Medtronic$33K
- Philips North America LLC$29K
- Pfizer$8K
- ZOLL Circulation Inc$4K
- Edwards Lifesciences$3K
- plus $5K from 24 others
Across 46 payments — averaging $4857.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$97K
- W. L. Gore & Associates, Inc.$97K
- CSL Behring$29K
What the payments were for
- Consulting fees$98,88171%
- Speaking & faculty fees$9,6387%
- Travel & lodging$15,88511%
- Food & beverage$15,62111%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 82 | $58,369 |
| Medtronic(2 entities) | 149 | $33,144 |
| Philips North America LLC | 52 | $29,415 |
| Pfizer | 7 | $7,705 |
| ZOLL Circulation Inc | 6 | $3,596 |
| Edwards Lifesciences | 29 | $2,757 |
| Boston Scientific | 16 | $1,275 |
| Shockwave Medical, Inc | 14 | $994 |
| Heartflow, Inc. | 3 | $440 |
| Abiomed | 11 | $313 |
| Amgen | 9 | $305 |
| W. L. Gore & Associates, Inc. | 8 | $276 |
| E.r. Squibb & Sons, L.L.C. | 9 | $268 |
| Opsens Inc. | 2 | $169 |
| Alnylam Pharmaceuticals Inc. | 3 | $167 |
| Penumbra, Inc. | 1 | $164 |
| Cordis US CORP. | 1 | $120 |
| Acist Medical Systems, Inc. | 2 | $104 |
| Novo Nordisk | 3 | $68 |
| Merck | 1 | $61 |
| Terumo Medical Corporation | 3 | $59 |
| Teleflex LLC | 4 | $57 |
| Spectrawave, Inc | 1 | $41 |
| GE HealthCare | 1 | $34 |
| Angiodynamics, Inc. | 1 | $34 |
| Biosense Webster, Inc. | 1 | $30 |
| Cathworks, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $28 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$27,248
- Dragonfly OCT$13,750
- OPTIS$12,104
- COROFLOW$11,940
- PRESSUREWIRE$11,463
- SYMPLICITY G3$8,550
- RESOLUTE ONYX$8,294
- DRAGONFLY OPSTAR$5,415
- TherOx DS2 Console$3,591
- Catheter$3,591
- Downstream Cartridge$3,591
- SUPERA$2,500
- VYNDAQEL$1,800
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,295
- (6575) Coronary Undivided$979
- GENERAL - THERAPIES$846
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$651
- COREVALVE EVOLUT R$547
- SAPIEN 3 Ultra RESILIA$422
- FFRct$296
How this compares
$140,058 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $42,023 |
| Atorvastatin Calcium | 115 | $2,529 |
| Metoprolol Succinate | 43 | $1,149 |
| ClopidogrelClopidogrel Bisulfate | 52 | $1,130 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 66 | $916 |
| Losartan Potassium | 73 | $821 |
| Carvedilol | 68 | $769 |
| Rosuvastatin Calcium | 40 | $709 |
| Lisinopril | 59 | $612 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $593 |
| Amiodarone Hcl | 14 | $592 |
| Spironolactone | 43 | $525 |
| Flecainide Acetate | 14 | $498 |
| Amlodipine Besylate | 23 | $326 |
| Torsemide | 21 | $291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $7,705 | $42,02331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Temple
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.